What is the “Title Element” in a Sequence Listing XML?
The “Title Element,” also known as the InventionTitle element, is a required component of the “general information” part of the “Sequence Listing XML” in patent applications. According to MPEP 2413.01(i), this element “need not be in English,” and applicants can provide multiple InventionTitle elements in different languages. To learn more: Sequence Listing XML InventionTitle Patent…
Read MoreWhat happens if I submit a non-English InventionTitle to the USPTO for an international application?
If you submit a non-English InventionTitle to the USPTO for an international application, where the USPTO is acting as the Receiving Office (RO/US), your application will be transferred to the International Bureau. According to MPEP 2413.01(i): “If non-English language is presented to RO/US for a ‘Sequence Listing XML,’ then RO/US will transfer the international application…
Read MoreCan I provide multiple InventionTitle elements in different languages?
Yes, you can provide multiple InventionTitle elements in different languages for your patent application. The MPEP 2413.01(i) states: “It is possible for an applicant to provide more than one InventionTitle element of the general information part in more than one language.” However, it’s important to note that for international applications where the USPTO is the…
Read MoreAre there language requirements for the InventionTitle element in international applications?
Yes, there are specific language requirements for the InventionTitle element in international applications. According to MPEP 2413.01(i): “When the USPTO is the Receiving Office (RO/US) for an international application, the English language is required for the InventionTitle element and any other language dependent free text element of the ‘Sequence Listing XML.’” If a non-English language…
Read MoreWhen did the requirements for the Title Element in Sequence Listing XML come into effect?
The requirements for the Title Element in Sequence Listing XML came into effect on July 1, 2022. According to the editor’s note in MPEP 2413.01(i): “This section is applicable to all applications filed on or after July 1, 2022, having disclosures of nucleotide and/or amino acid sequences as defined in 37 CFR 1.831(b).” This means…
Read More